BE563376A - - Google Patents
Info
- Publication number
- BE563376A BE563376A BE563376DA BE563376A BE 563376 A BE563376 A BE 563376A BE 563376D A BE563376D A BE 563376DA BE 563376 A BE563376 A BE 563376A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- active ingredient
- administered
- composition according
- calming
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000001914 calming effect Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 239000008014 pharmaceutical binder Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- HCCHMKIFYLZSOQ-UHFFFAOYSA-N n-cyclopropylcyclopropanecarboxamide Chemical compound C1CC1C(=O)NC1CC1 HCCHMKIFYLZSOQ-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000036524 ataraxia Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE563376A true BE563376A (enrdf_load_stackoverflow) |
Family
ID=184635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE563376D BE563376A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE563376A (enrdf_load_stackoverflow) |
-
0
- BE BE563376D patent/BE563376A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1015972A5 (fr) | Composes organiques. | |
| EP0287488B1 (fr) | Médicament, produit diététique et produit d'hygiène sous la forme d'une composition pulvérulente obtenue par adsorption de principes actifs sur un sucre à dissolution rapide et procédé d'obtention de ladite composition | |
| EP0593601A1 (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| BE1001204A5 (fr) | Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments. | |
| FR2624863A1 (fr) | Nouvelle forme cristalline de la ciclosporine, sa preparation et les compositions pharmaceutiques la contenant | |
| CA2123232C (fr) | Compositions pharmaceutiques a base d'ebastine ou de ses analogues | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FR2524314A1 (fr) | Medicament a action salidiuretique, contenant des dihydropyridines | |
| BE563376A (enrdf_load_stackoverflow) | ||
| BE507692A (fr) | Perfectionnements apportés aux procedés de préparation de produits thérapeutiques | |
| BE1004243A3 (fr) | Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation. | |
| FR2561104A1 (fr) | Etoposide sous forme de dose destinee a une utilisation orale | |
| CA1059913A (fr) | Compositions pharmaceutiques | |
| FR2467596A1 (fr) | Compositions pharmaceutiques de tiaramide ou de son sel et d'un agent reglant la dissolution, a longue duree d'action | |
| LU85242A1 (fr) | Nouvelle association medicamenteuse | |
| BE563436A (enrdf_load_stackoverflow) | ||
| CH641775A5 (fr) | N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment. | |
| FR2462161A1 (fr) | Compositions therapeutiques a base de composes azoiques | |
| BE1001263A4 (fr) | Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes. | |
| BE558088A (enrdf_load_stackoverflow) | ||
| BE545007A (enrdf_load_stackoverflow) | ||
| US20250049924A1 (en) | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | |
| BE698432A (enrdf_load_stackoverflow) | ||
| Milner et al. | The Potentiation by Amitriptyline of Liver Changes Induced by Ethanolin Mice |